Annexin A1: The dawn of ischemic stroke (Review)

Mol Med Rep. 2025 Mar;31(3):62. doi: 10.3892/mmr.2024.13427. Epub 2025 Jan 3.

Abstract

Ischemic stroke is a prevalent clinical condition that poses a significant global challenge. Developing innovative strategies to address this issue is crucial. Annexin A1 (ANXA1), a key member of the annexin superfamily, performs various functions, such as inhibiting inflammatory factor release, promoting phagocytosis, and blocking leukocyte migration. Evidence indicates that ANXA1 plays a pivotal role in the pathogenesis of ischemic stroke. The present article reviews involvement of ANXA1 in anti‑atherosclerosis, inflammatory processes, blood‑brain barrier protection, platelet aggregation and anti‑apoptotic mechanisms. The potential applications of ANXA1 in treating ischemic stroke are also explored.

Keywords: annexin‑A1; arteriosclerosis; blood‑brain barrier; inflammation; ischemic stroke.

Publication types

  • Review

MeSH terms

  • Animals
  • Annexin A1* / genetics
  • Annexin A1* / metabolism
  • Apoptosis
  • Blood-Brain Barrier / metabolism
  • Humans
  • Inflammation / metabolism
  • Inflammation / pathology
  • Ischemic Stroke* / metabolism
  • Ischemic Stroke* / pathology
  • Platelet Aggregation

Substances

  • Annexin A1
  • ANXA1 protein, human

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant nos. 81973618 and 81503422), the Henan science and technology research and development plan joint fund (grant no. 242301420094), the Key Scientific Research Project of Higher Education of Henan (grant no. 25A360005) and the Natural Science Foundation of Henan (grant no. 202300410399).